Manufacturer
23 recalls in our database name Cipla USA, Inc. as the manufacturing or recalling firm.
Of the 23 recalls from Cipla USA, Inc. we have scored against our rubric, 3 (13%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 2 (9%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Cipla USA, Inc. is recalling Cinacalcet Hydrochloride Tablets, 60 mg due to cGMP deviations involving the presence of N-nitroso-cinacalcet above acceptable daily intake levels.
Cipla USA, Inc. is recalling Cinacalcet Hydrochloride 90 mg tablets (Lot #5PB0563, expiring 4/30/2027) distributed nationwide due to the presence of N-nitroso-cinacalcet above acceptable daily intake levels, a manufacturing deviation.
Cipla USA, Inc. is recalling Cinacalcet Hydrochloride 30 mg tablets due to the presence of N-nitroso-cinacalcet above the acceptable daily intake. The affected product was distributed nationwide.
Cipla is recalling Cinacalcet Hydrochloride Tablets, 30 mg, over CGMP deviations and the presence of N-Nitroso Cinacalcet above the acceptable daily intake limit. 113,336 bottles are affected.
Cipla is recalling Cinacalcet Hydrochloride Tablets, 90 mg, over CGMP deviations and the presence of N-Nitroso Cinacalcet above the acceptable daily intake limit. 63,192 bottles are affected.
Cipla is recalling Cinacalcet Hydrochloride Tablets, 60 mg, over CGMP deviations and the presence of N-Nitroso Cinacalcet above the acceptable daily intake limit. 96,096 bottles are affected.
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL prefilled syringes for lack of assurance of sterility, following an FDA observation of deficiencies in visual inspection at the contract manufacturing site.
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL prefilled syringes supplied with a safety needle, citing lack of assurance of sterility. 54,583 syringes are affected.
Cipla USA is recalling three lots of Nilotinib Capsules 150 mg after out-of-specification results in description and visual appearance testing at six-month long-term stability.
Cipla USA is recalling one lot of Nilotinib Capsules 200 mg after out-of-specification results in description and visual appearance testing at six-month long-term stability.
Cipla USA is recalling 92,376 tubes of Diclofenac Sodium Topical Gel 1% after the batch failed pH specifications.
Cipla USA is recalling 15,221 prefilled syringes of Lanreotide Injection, 120 mg/0.5 mL, over the presence of particulate matter.
Chetak New York is recalling Deep-brand frozen garlic cloves after the product tested positive for Salmonella. The FDA has classified the action as Class I.
Chetak New York is recalling Deep-brand frozen jamun after the product tested positive for Salmonella. The FDA has classified the action as Class I.
Cipla USA is recalling 12,576 bottles of Cinacalcet Hydrochloride Tablets, 90 mg, over the presence of N-nitroso-cinacalcet above the acceptable daily intake limits.
Cipla USA is recalling 63,504 bottles of Cinacalcet Hydrochloride Tablets, 30 mg, over the presence of N-nitroso-cinacalcet above the acceptable daily intake limits.
Cipla USA is recalling 1,180 boxes of Lanthanum Carbonate chewable tablets, 1000mg, from a further lot after an out of specification hardness test result.
Cipla Albuterol Sulfate Inhalation Aerosol, 90 mcg, lot 4IB0519, is recalled nationwide after out-of-specification particle size distribution results at the 12-month stability point. 20,352 packs are affected.
Budesonide Inhalation Suspension 0.5 mg/2 mL is being recalled for lack of assurance of sterility after a market complaint was received for leakage and an empty ampoule. 13,680 ampoules affected.
Cipla USA is recalling Lanthanum Carbonate Chewable Tablets (1000mg) distributed nationwide due to complaints of crushed and broken tablets that fail manufacturing specifications.
Cipla USA is recalling Lanthanum Carbonate Chewable Tablets, 1000mg due to complaints of crushed and broken tablets. The recall affects 1,875 boxes distributed nationwide.
Cipla USA recalls Ipratropium Bromide and Albuterol Sulfate inhalation solution due to short fill in unit-dose vials. Some vials contain less medication than labeled, affecting dosage.
Cipla USA is recalling 278,538 albuterol sulfate inhalers nationwide with specific lot numbers due to defective valve gaskets that cause empty inhalers or medication leakage. Check your lot number and contact your healthcare provider if affected.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
Cipla
Indian multi-national pharmaceutical and biotechnology company
Source: Wikidata (Q905572), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.